The inflammatory process correction in rats with benign prostatic hyperplasia

Abstract

Benign prostatic hyperplasia (BPH) is a common disease which affects 50-80% of the male population in old age. Based on the important role of chronic inflammation in the pathogenesis of BPH the concept of its pharmacological treatment has also changed and an important property of drugs is the presence of antiinflammatory effects. The purpose of the work was to evaluate the effect of Chondroitin sulfate, Bioglobin-U and Tribestan on inflammation in experimental benign prostatic hyperplasia and in comparison with the effects of other prostatoprotectors. BPH was caused by intraperitoneal administration of sulpiride (Eglonil) at a dose of 40 mg/kg of animal body weight during 30 days. The model represents the development of lateral parts hyperplasia of the prostate, which correlates with similar pathological changes in the human prostate. After rats' BPH were given Chondroitin sulphate at a dose of 60 mg/kg, Chondroitin sulphate in combination with Tribestan at a dose of 60 mg /kg, Tribestan (manufactured by Sopharma, Bulgaria) at a dose of 60 mg/kg, and Bioglobin-U (a proteinised water-salt extract from a human placenta including polypeptides 3.5–7 %, aminoacids 50–60 %, amino sugars 4–5 %, hexuronic acids 8–9 %, produced by CJSC Biolik, Kharkiv) at a dose of 200 μl/kg. The comparison drug was Prostaplant forte produced by Schwabe company, Germany. The drugs were administered from the 30th to the 51st day of the experiment after completion of BPH modeling. The level of C-reactive protein (CRP), sedimentation rate of erythrocytes (SRE), and white blood cell count have been studied. It is proved that the model of prostatic hyperplasia is characterized by an increase in the number of leukocytes and SRE and CRP concentration and the degree of their growth can be attributed to manifestations of chronic inflammation. The studied drugs showed pronounced anti-inflammatory properties and this is confirmed by a decrease of leukocytes number and SRE and the concentration of CRP in rats with experimental benign prostatic hyperplasia. According to the results of a study of chondroitin sulfate, Bioglobin-U hadmore pronounced antiinflammatory properties. Chondroitin sulfate reduced SRE more effectively than the comparison drug Prostaplant forte. The studied preparations of Сhondroitin sulfate and Bioglobin-U which have pronounced anti-inflammatory properties can be recommended for use in benign prostatic hyperplasia to reduce the manifestations of inflammation.